Veterinary Endotracheal Tubes MarketSize, Share & Industry Analysis, 2026-2034By ProductBy AnimalBy End UseBy MaterialBy Distribution Channel

A veterinary endotracheal tube is a flexible airway device placed into an animal's trachea during general anesthesia to maintain a clear airway, deliver anesthetic gases and oxygen, and protect the lungs from fluids or debris during surgical and dental procedures. Tubes are supplied in cuffed and uncuffed designs and in a range of sizes and materials to fit species and breeds from small cats to large dogs. Buyers are general veterinary hospitals, specialty and referral surgical centers, and general-practice clinics that perform anesthesia-based procedures, purchasing either directly from manufacturers or through veterinary supply distributors.

The global veterinary endotracheal tubes market stood at USD 11.72 million in 2025. A forecast-period rate of 7.72% takes it to USD 22.8 million by 2034, and the study reports every year in between, passing USD 8 million in 2020, USD 10.85 million in 2024, USD 12.58 million in 2026 and USD 16.9 million in 2030.

62.5% of 2025 revenue sits in Cuffed, worth USD 7.33 million and rising to USD 15.05 million at 66% by 2034, the largest product line in both years. Growth is fastest in Cuffed at 8.34% and slowest in Uncuffed at 6.6%. Cuffed take share over the period; Uncuffed give it up while still growing in absolute terms.

Cut by animal, the largest line is Dog: 58% of 2025 revenue, worth USD 6.8 million, and 56% at USD 12.77 million by 2034. Cat grows faster at 8.41% against 7.3%, moving from 33% of revenue to 35% by 2034. Both this axis and the product one divide the same revenue, which is why they are alternative views rather than components.

Geographically, 38.05% of 2025 revenue sits in North America (USD 4.46 million rising to USD 7.98 million) ahead of Europe at 26.96% and USD 3.16 million. Middle East and Africa is smallest, at 4.95%. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates rather than spreading across all five regions.

Coverage extends to five regions, two product lines and five segmentation axes over the full fifteen years. The 2025 total itself is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• A forecast-period rate of 7.72% takes the market from USD 11.72 million in 2025 to USD 22.8 million in 2034, against 7.94% recorded over the 2020-2025 historical period.
• Cuffed is the largest product line at USD 7.33 million in 2025, a 62.5% share, reaching USD 15.05 million and 66% of revenue by 2034.
• The bull case puts 2034 revenue at USD 25.54 million and the bear case at USD 20.06 million, either side of the USD 22.8 million base case, each with its own stated assumption in the full report.
• 38.05% of 2025 revenue is generated in North America, worth USD 4.46 million and rising to USD 7.98 million by 2034; Middle East and Africa is smallest at 4.95%.
• Within North America, the United States is the worked country example, at USD 3.75 million in 2025; 84% of regional revenue in the base year, and USD 6.7 million by 2034.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Three movements define the forecast period in the global veterinary endotracheal tubes market: how the product mix changes, where regional weight shifts, and the rate at which the total compounds.

All three are changes in mix rather than in direction: nothing contracts, and the movement is in which lines and regions absorb the new revenue.

The product mix tilts toward Cuffed. The widest spread on the product axis is between Cuffed at 8.34% and Uncuffed at 6.6%. Shares follow: 62.5% to 66% for Cuffed, 37.5% to 34% for Uncuffed. Neither contracts: USD 7.33 million becomes USD 15.05 million, USD 4.39 million becomes USD 7.75 million. What the spread decides is which of them a supplier's revenue is exposed to.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 22.01% of revenue in 2025 to 26.01% in 2034, worth USD 2.58 million rising to USD 5.93 million; Latin America moves from 8.02% of revenue in 2025 to 8.51% in 2034, worth USD 0.94 million rising to USD 1.94 million; Middle East and Africa moves from 4.95% of revenue in 2025 to 5.48% in 2034, worth USD 0.58 million rising to USD 1.25 million. The offsetting side is North America at 38.05% moving to 35%, Europe at 26.96% moving to 25%, none of which contracts. That makes the regional split worth reading rather than scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

The series never breaks trajectory. Reading the series: USD 8 million in 2020, USD 10.85 million in 2024, USD 11.72 million in 2025, USD 12.58 million in 2026, USD 16.9 million in 2030 and USD 22.8 million in 2034. No year breaks the trajectory, and the 7.72% forecast rate compares with 7.94% recorded over 2020-2025, a continuation rather than an inflection. That moves the planning question away from timing a turn and onto the product and regional mixes, where the actual movement is.

Growth is concentrated in Cuffed

Separate the 7.72% into its parts and three show up: an already-large base compounding, the product mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 20.06 million rather than USD 22.8 million by 2034

Where the forecast could be beaten

Revenue is concentrated in Cuffed

North America holds 38.05% of the global veterinary endotracheal tubes market in 2025, worth USD 4.46 million on the way to USD 7.98 million by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

Share settles at 35% in 2034, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Cuffed leads here as it does globally, at 62.5% of 2025 revenue, and Cuffed again grows fastest at 8.34%. Per-axis and per-country detail for North America sits in the full report.

The United States is the largest market within North America, generating USD 3.75 million in 2025 and projected to reach USD 6.7 million by 2034. 84% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. The region itself runs USD 4.46 million to USD 7.98 million over the same period, and this is the market carrying the country-level detail in the full report.

The product pattern in the United States is the global one: 62.5% of 2025 revenue in Cuffed, 66% by 2034, against 8.34% growth in Cuffed taking it from 62.5% to 66%. Its 84% weight in North America means those movements carry straight into the regional totals. The full report reports the United States by product separately.

In the United States, veterinary endotracheal tubes fall outside the FDA's premarket review pathway that governs devices intended for human use, since the agency's device authority is scoped to human medicine. Oversight instead rests on general manufacturing and quality practice, professional veterinary standards set by bodies such as the American Veterinary Medical Association, and voluntary conformity with recognized industry and materials standards for medical-grade tubing. Suppliers are expected to substantiate biocompatibility and performance through their own quality systems, and labelling should clearly identify the product's veterinary-only use so it is not mistaken for a human-use device. State veterinary practice regulation governs clinical use, adding professional oversight beyond manufacturer-level quality assurance.

The suppliers tracked in this study (Medtronic, Conduct Science, Harvard Apparatus (Harvard Bioscience Inc.), Jorgensen Laboratories, Vetamac, Inc., Kent Scientific Corporation, MILA International, Inc., Cook Medical (Veterinary Products), Kruuse A/S, Eickemeyer and Vygon (Vetflex)) compete in the United States across the product lines above. Volume and growth sit in the same line — Cuffed, at 62.5% of 2025 revenue and 8.34% growth. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 16% of regional revenue and 6.1% of the global total, worth USD 0.71 million in 2025 and USD 1.28 million by 2034.

26.96% of the global veterinary endotracheal tubes market sits in Europe in 2025, worth USD 3.16 million and reaches USD 5.7 million by 2034. It is a leading region on this axis, second by revenue throughout the period.

By 2034 the share stands at 25%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Cuffed leads here as it does globally, at 62.5% of 2025 revenue, and Cuffed again grows fastest at 8.34%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

Germany is the largest market within Europe, generating USD 0.95 million in 2025 and projected to reach USD 1.71 million by 2034. It accounts for 30% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 3.16 million to USD 5.7 million over the same period, and this is the market carrying the country-level detail in the full report.

The product pattern in Germany is the global one: 62.5% of 2025 revenue in Cuffed, 66% by 2034, against 8.34% growth in Cuffed taking it from 62.5% to 66%. Its 30% weight in Europe means those movements carry straight into the regional totals. Revenue by product for Germany is reported separately in the full report.

In Germany, as across the European Union, veterinary endotracheal tubes sit outside the Medical Device Regulation, which is scoped to products intended for human patients, so there is no harmonised premarket approval route specific to veterinary instruments of this kind. Placing such tubes on the market instead relies on the General Product Safety framework and on voluntary conformity with recognised international standards covering materials, biocompatibility and airway-device design, which many manufacturers adopt to demonstrate quality even without a mandatory certification mark. Germany's federal veterinary authority, the Bundesamt für Verbraucherschutz und Lebensmittelsicherheit, concentrates its oversight on veterinary medicinal products rather than instruments, leaving device-level assurance to manufacturer quality systems, distributor due diligence and the professional judgement of veterinarians who select and use the equipment in practice.

In Germany the field is Medtronic, Conduct Science, Harvard Apparatus (Harvard Bioscience Inc.), Jorgensen Laboratories, Vetamac, Inc., Kent Scientific Corporation, MILA International, Inc., Cook Medical (Veterinary Products), Kruuse A/S, Eickemeyer and Vygon (Vetflex). Volume and growth sit in the same line — Cuffed, at 62.5% of 2025 revenue and 8.34% growth.

6.7% of global revenue is generated in the United Kingdom; USD 0.79 million in 2025, reaching USD 1.43 million in 2034, and 25% of Europe.

5.4% of global revenue is generated in France; USD 0.63 million in 2025, reaching USD 1.14 million in 2034, and 20% of Europe.

22.01% of the global veterinary endotracheal tubes market sits in Asia Pacific in 2025, worth USD 2.58 million on the way to USD 5.93 million by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

26.01% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 7.72% global rate, which is what makes this region worth reading separately rather than scaling from the total.

Within the region the product split tracks the global one; 62.5% of 2025 revenue in Cuffed, fastest growth of 8.34% in Cuffed. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

USD 0.72 million of Asia Pacific's 2025 revenue is generated in Japan, the region's largest market, reaching USD 1.66 million by 2034. 28% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 2.58 million in 2025 and USD 5.93 million in 2034, it is the country the full report breaks out in detail.

The product pattern in Japan is the global one: 62.5% of 2025 revenue in Cuffed, 66% by 2034, against 8.34% growth in Cuffed taking it from 62.5% to 66%. With 28% of Asia Pacific concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Japan carries its own product breakdown in the full report.

In Japan, veterinary medical products are administered separately from human healthcare products, with the Ministry of Agriculture, Forestry and Fisheries taking the lead role rather than the health ministry that governs human-use devices. Instruments such as endotracheal tubes intended solely for animal anaesthesia generally fall outside the strict premarket approval pathway applied to human medical devices, with oversight instead emphasising manufacturer quality control, accurate labelling of intended veterinary use, and conformity with recognised international standards for airway and anaesthesia equipment. Distribution through licensed veterinary wholesalers and use under the supervision of registered veterinarians provide additional practical oversight, so responsibility for safety and performance rests largely on the manufacturer's own quality assurance.

Medtronic, Conduct Science, Harvard Apparatus (Harvard Bioscience Inc.), Jorgensen Laboratories, Vetamac, Inc., Kent Scientific Corporation, MILA International, Inc., Cook Medical (Veterinary Products), Kruuse A/S, Eickemeyer and Vygon (Vetflex) are the suppliers covered in Japan. Volume and growth sit in the same line — Cuffed, at 62.5% of 2025 revenue and 8.34% growth.

China is sized at USD 0.62 million in 2025, rising to USD 1.42 million by 2034; 5.3% of global revenue and 24% of Asia Pacific. It is reported separately from Japan across every segmentation axis in the full report.

Australia is sized at USD 0.41 million in 2025, rising to USD 0.95 million by 2034; 3.5% of global revenue and 16% of Asia Pacific. It is reported separately from Japan across every segmentation axis in the full report.

Latin America holds 8.02% of the global veterinary endotracheal tubes market in 2025, worth USD 0.94 million rising to USD 1.94 million in 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Share climbs to 8.51% by 2034, on growth above the market's own 7.72%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

The product mix reported at global level applies here, with Cuffed the largest line at 62.5% of 2025 revenue and Cuffed the fastest-growing at 8.34%. Latin America is reported axis by axis and country by country in the full study.

The largest single market in Latin America is Brazil, at USD 0.52 million in 2025 and USD 1.07 million in 2034. At 55% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Set against USD 0.94 million and USD 1.94 million for the region, it is why this market rather than a smaller one is the one reported in full.

The product pattern in Brazil is the global one: 62.5% of 2025 revenue in Cuffed, 66% by 2034, against 8.34% growth in Cuffed taking it from 62.5% to 66%. Because the country carries 55% of Latin America, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. Brazil carries its own product breakdown in the full report.

In Brazil, veterinary health products, including instruments used in animal anaesthesia such as endotracheal tubes, are regulated by the Ministério da Agricultura, Pecuária e Abastecimento rather than by the national health surveillance agency that governs products for human use. Placing such a device on the market generally requires registration with the ministry's veterinary products directorate, along with labelling that clearly states its veterinary-only indication and manufacturing conducted under recognised quality and good-manufacturing standards. Importers and domestic manufacturers are expected to maintain technical documentation supporting the safety and material quality of the tube, and distribution runs through channels authorised to handle veterinary health products, with clinical use overseen by licensed veterinarians rather than a separate device-specific inspection regime.

In Brazil the field is Medtronic, Conduct Science, Harvard Apparatus (Harvard Bioscience Inc.), Jorgensen Laboratories, Vetamac, Inc., Kent Scientific Corporation, MILA International, Inc., Cook Medical (Veterinary Products), Kruuse A/S, Eickemeyer and Vygon (Vetflex). Volume and growth sit in the same line — Cuffed, at 62.5% of 2025 revenue and 8.34% growth.

Mexico is sized at USD 0.28 million in 2025, rising to USD 0.58 million by 2034; 2.4% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

Middle East and Africa holds 4.95% of the global veterinary endotracheal tubes market in 2025, worth USD 0.58 million with USD 1.25 million projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

5.48% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 7.72% global rate, which is what makes this region worth reading separately rather than scaling from the total.

The product mix reported at global level applies here, with Cuffed the largest line at 62.5% of 2025 revenue and Cuffed the fastest-growing at 8.34%. The full report breaks Middle East and Africa out along every axis and by country.

The largest single market in Middle East and Africa is South Africa, at USD 0.2 million in 2025 and USD 0.44 million in 2034. It accounts for 35% of regional revenue in the base year, the largest single share without dominating the region outright. Set against USD 0.58 million and USD 1.25 million for the region, it is why this market rather than a smaller one is the one reported in full.

Composition here matches the global split: the largest line is Cuffed at 62.5% of 2025 revenue, easing to 66% by 2034, and the fastest is Cuffed at 8.34%, from 62.5% to 66%. Since 35% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-product revenue for South Africa appears on its own in the full report.

In South Africa, veterinary remedies and stock remedies are registered through the Registrar of Veterinary Medicines within the national department responsible for agriculture, under the long-standing statute governing farm feeds, agricultural remedies and stock remedies, though that registration pathway is aimed primarily at medicinal and biological products rather than physical instruments. An endotracheal tube used in animal anaesthesia is more likely to fall under general consumer and product safety law and voluntary conformity with recognised national and international standards for medical-grade tubing, with the South African Bureau of Standards providing relevant reference specifications. Suppliers are expected to label the product clearly for veterinary use, support material and performance claims through their own quality documentation, and rely on the professional oversight of registered veterinarians who select and use the device in clinical settings.

Competition in South Africa runs between the suppliers this study tracks: Medtronic, Conduct Science, Harvard Apparatus (Harvard Bioscience Inc.), Jorgensen Laboratories, Vetamac, Inc., Kent Scientific Corporation, MILA International, Inc., Cook Medical (Veterinary Products), Kruuse A/S, Eickemeyer and Vygon (Vetflex). Volume and growth sit in the same line — Cuffed, at 62.5% of 2025 revenue and 8.34% growth.

Within Middle East and Africa, Saudi Arabia accounts for 30% of regional revenue and 1.5% of the global total, worth USD 0.17 million in 2025 and USD 0.38 million by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, Animal, End Use, Material, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.